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Abstract Parkinson’s disease is the second most common neu-
rodegenerative disease, and results from loss of dopaminergic
neurons in the substantia nigra. The aggregation and ¢brillation
of K-synuclein in the form of intracellular proteinaceous aggre-
gates (Lewy bodies and Lewy neurites) have been implicated as
a causative factor in this disease, as well as in several other
neurodegenerative disorders, including dementia with Lewy
bodies, Lewy body variant of Alzheimer’s disease, multiple sys-
tem atrophy and Hallervorden^Spatz disease. Thus, the aggre-
gated forms of K-synuclein play a crucial role in the patho-
genesis of the synucleinopathies. However, the molecular mech-
anisms underlying K-synuclein aggregation into speci¢c ¢lamen-
tous inclusions remained unknown until recently. Data on the
aggregation and ¢brillation properties of human K-, L- and
Q-synucleins, mouse K-synuclein and familial Parkinson’s disease
mutants of human K-synuclein (A30P and A53T) are analyzed
in order to shed light on the amino acid determinants of synu-
clein aggregation. * 2002 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: Parkinson’s disease; Synucleinopathy;
Neurodegenerative disorder; K-Synuclein; Fibrillation;
Aggregation
1. Introduction
Parkinson’s disease (PD), the second most common neuro-
degenerative disease, results from loss of dopaminergic neu-
rons in the substantia nigra. Some surviving nigral dopaminer-
gic neurons contain cytosolic ¢lamentous inclusions known as
Lewy bodies (LBs) and Lewy neurites (LNs) [1,2]. Besides the
substantia nigra, LBs and LNs also are found in other brain
regions, such as the dorsal motor nucleus of the vagus, the
nucleus basalis of Meynert, and the locus coeruleus [2]. In
addition, abundant LBs and LNs in cerebral cortex are neuro-
phathological hallmarks of dementia with LBs, a common
late-life dementia that is clinically similar to Alzheimer’s dis-
ease [3], in LB variant of Alzheimer’s disease [4], di¡use LB
disease [5], multiple system atrophy [4,6] and several other
neurodegenerative disorders. The major ¢brillar material of
LBs and LNs was shown to be K-synuclein [7,8]. Moreover,
two di¡erent missense mutations in the K-synuclein gene, cor-
responding to A53T and A30P substitutions in K-synuclein,
have been identi¢ed in two kindreds with autosomal-domi-
nantly inherited, early-onset PD [9,10]. The production of
wild-type (WT) human K-synuclein in transgenic mice [11]
or of WT, A30P and A53T human K-synuclein in transgenic
£ies [12] leads to motor de¢cits and neuronal inclusions rem-
iniscent of PD. It has been established that all three proteins,
as well as the 1^87 and 1^120 truncated forms of recombinant
K-synuclein, are able to assemble readily into ¢laments in
vitro, with morphologies and staining characteristics similar
to those extracted from disease-a¡ected brain [13^15]. More-
over, it has been shown that ¢brils formed in vitro from
K-synuclein and two mutant forms linked to PD are typical
amyloid, i.e. structurally and morphologically they resembles
¢brils formed by other amyloidogeneic proteins [14^16]. In-
terestingly, the peptide derived from the central hydrophobic
region of K-synuclein represents a second major intrinsic con-
stituent of Alzheimer’s plaques. This 35-amino-acid peptide,
known as NAC (Non-AL Component of Alzheimer’s disease
amyloid), was shown to amount to about 10% of the amyloid
plaque [17]. These observations indicate that K-synuclein is a
key player in the pathogenesis of several neurodegenerative
disorders.
2. Peculiarities of the K-synuclein amino acid sequence
K-Synuclein was ¢rst described as a neuron-speci¢c protein
localized to the nucleus and presynaptic nerve terminals [18].
K-Synuclein from di¡erent organisms possesses a high degree
of sequence conservation. For example, mouse and rat K-syn-
ucleins are identical throughout the ¢rst 93 residues, and hu-
man and canary proteins di¡er from them by only two resi-
dues [19]. The primary sequence of human K-synuclein is
composed of 140 amino acid residues. It can be subdivided
into three regions (see Fig. 1):
1. Residues 1^60 form the N-terminal region. It includes the
sites of both familial PD mutations and contains four 11-
amino-acid imperfect repeats with a highly conservative
hexamer motif (KTKEGV). The N-terminal region is pre-
dicted to form amphipathic K-helices, typical of the lipid-
binding domain of apolipoproteins ([19,20] see below).
2. The central region comprises the highly amyloidogenic
NAC sequence (residues 61^95) [17,21]. It contains two
additional KTKEGV repeats.
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3. Finally, residues 96^149 constitute the C-terminal region.
This part of K-synuclein is enriched in acidic residues and
prolines, suggesting that it adopts a disordered conforma-
tion (see below). Three highly conserved tyrosine residues,
which are considered as a family signature of K- and L-
synucleins, are located in this region.
An important characteristic of the K-synuclein primary
structure is six imperfect repeats within the ¢rst 95 residues,
resulting in a variation in hydrophobicity [17,19,20^22] with a
strictly conserved periodicity of 11 [20]. Such a periodicity is
characteristic of the amphipathic lipid-binding K-helical do-
mains of apolipoproteins [19,20], which have been extensively
studied and assigned to subclasses according to their unique
structural and functional properties [23,24]. K-Synuclein
shares the de¢ning properties of the class A2 lipid-binding
helix, distinguished by clustered basic residues at the polar^
apolar interface, positioned M100‡ from the center of apolar
face; predominance of lysines relative to arginines among
these basic residues; and several glutamate residues at the
polar surface [23^25]. In agreement with these structural fea-
tures, K-synuclein (which belongs to the family of natively
unfolded proteins, which show little or no ordered structure
under physiological conditions [26^28]) binds speci¢cally to
synthetic vesicles containing acidic phospholipids [22,25].
This binding was shown to be accompanied by a dramatic
increase in K-helix content [22,25].
3. Amino acid determinants of K-synuclein aggregation and
¢brillation
3.1. Role of the NAC region
Analysis of literature data allows some conclusions to be
made about the amino acid determinants of K-synuclein ag-
gregation and ¢brillation. First of all, the crucial role of the
central hydrophobic region, known as the NAC peptide, is
implicated by several lines of evidence.
1. As already mentioned, NAC is the second major compo-
nent of amyloid plaques in Alzheimer’s brain [17], and
readily forms ordered ¢brils in vitro [17,21,29]. Moreover,
NAC can seed AL(1^40) amyloidogenesis and AL can also
seed amyloid formation by NAC [21].
2. Although L-synuclein is highly homologous to K-synuclein,
it does not ¢brillate [30^32]. It has been suggested that this
is because of the lack of an 11-amino-acid segment within
the central part of the NAC domain (corresponding to
residues 73 to 83 of K-synuclein) (see Fig. 1).
3. The rate of K-synuclein association in vitro was shown to
decrease after the substitution of Ala76 with charged ami-
no acids (either Arg or Glu) [33]. Furthermore, the deletion
of amino acid residues 71^82 in human K-synuclein pre-
vented protein aggregation [33].
4. Finally, analysis of the N-terminal sequence of NAC estab-
lished the existence of some similarity to a region crucial
for aggregation of three other amyloidogenic polypeptides,
AL, prion protein, and islet amyloid polypeptide. Speci¢-
cally, a four-residue motif, Gly-Ala-XX, where X is an
amino acid with an aliphatic side chain, has been shown
to be common to all four peptides [21,34,35].
These observations strongly argue in the favor of direct
involvement of the NAC domain in the pathologic aggrega-
tion of K-synuclein. Several ‘dissection’ studies have been per-
formed in order to understand which particular part of NAC
is responsible for its tendency to form ¢brils [30,34^37]. It has
been shown that the amyloidogenicity is not uniformly dis-
tributed within NAC [33]. For example, the C-terminal half
of the peptide (NAC residues 19^35, i.e. residues 79^95 in
K-synuclein) does not ¢brillate, whereas the N-terminal frag-
ment can ¢brillate [36,37]. Moreover, although some ¢brils
were detected for the NAC fragment 1^18 (61^78 in K-synu-
clein), it did not precipitate out of solution to a signi¢cant
degree. The only NAC fragment that readily formed ¢brils
and precipitated out of solution was NAC 3^18 (or 63^78 in
K-synuclein) [30]. Finally, NAC fragment 8^18 (68^78 in
K-synuclein sequence) also showed propensity to ¢brillate
[36] (see Fig. 2). Interestingly, all the peptides considered so
far contained a four-residue motif, Gly68-Ala69-Val70-Val71,
which was assumed to be a signature motif of amyloidogenic
proteins [34,35].
Another candidate for a major player in K-synuclein ¢bril
formation, namely fragment 71^82, has been revealed in an
independent investigation, inspired by the di¡erence in aggre-
gation behavior of K- and L-synucleins [33] (see Fig. 2). It has
been shown that K-synuclein with residues 71^82 deleted does
not ¢brillate. Also, the rate of K-synuclein ¢brillation was
signi¢cantly reduced as a result of substitution of Ala76
with charged Arg or Glu. On the other hand, a synthetic
peptide, corresponding to this 12-amino-acid stretch, ¢bril-
lated by itself and promoted ¢brillation of full-length human
K-synuclein in vitro [33]. Importantly, this fragment does not
have a ‘signature motif’ GAXX (see Fig. 2), which is also
lacking in ¢brillation-prone Q-synuclein thus calling into ques-
tion the signi¢cance of the ‘signature motif’ model of El-Ag-
naf et al. [34,35].
Interestingly, it appears that there is a limitation in length
Fig. 1. K-Synuclein sequence. The two sites of early-onset PD-linked
mutations (positions 30 and 53) are highlighted.
Fig. 2. Aligned sequences of the NAC regions of human K-, L- and
Q-synucleins, mouse K-synuclein and six NAC fragments capable of
¢brillation. GAVV was proposed as a signature motif of four amy-
loidogenic proteins, K-synuclein, AL, prion protein, and islet amy-
loid polypeptide [30]. The Ala residue, mutation of which to either
an Arg or Glu decreased the rate of K-synuclein polymerization
[29], is highlighted. A potential ‘inhibitory’ Ser87Asn substitution is
shown in bold-italic.
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for peptides derived from NAC to be amyloidogenic [36].
In fact, short NAC fragments 8^15(68^75), 8^16(68^76),
9^16(69^76) and 12^18(72^78) were shown to remain abso-
lutely soluble over the three-day incubation, whereas NAC
8^18(68^78) showed signi¢cant aggregation, with V70% of
the peptide coming out of solution after three days [36].
Note that two non-aggregating peptides NAC 8^15 and 8^
16 contained the ‘signature’ GAVV motif.
Stretches of hydrophobic amino acid residues, commonly
found in amyloidogenic proteins, are usually considered as
important prerequisites for aggregation and ¢brillation. Three
consecutive repeats of the GXXX motif (where X is any of
Gly, Ala, Val, Ile, Leu, Phe, Tyr, Trp, Thr, Ser or Met) were
implicated in the amyloidogenic behavior of several amyloid-
ogenic proteins [38]. NAC contains three GXXX motifs,
68GAVV71, 73GVTA76 and 84GAGS87, with two of them being
located within the non-amyloidogenic C-terminal half of NAC
(see Fig. 2). On the other hand, the highly amyloidogenic
peptide NAC 11^22 (71^82) [33] contains only a single
GXXX motif. Furthermore, two out of three such motifs
are eliminated by substitutions of glycine with glutamate in
¢brillation-prone Q-synuclein (Fig. 2). These observations
bring into question the validity of the model of three consec-
utive GXXX repeats as a major amino acid determinant of
¢brillation.
Some additional lessons can be taken from the comparison
of the NAC regions derived from di¡erent members of the
synuclein family. Fig. 2 shows that the NAC regions of hu-
man K- and Q-synucleins are rather di¡erent, as they have only
18 identical residues out of 35. On the other hand, such di-
vergence does not signi¢cantly a¡ect the distribution of hy-
drophobicity within their amino acid sequences and Fig. 3A
illustrates that the NAC domains of all members of the syn-
uclein family possess very similar pro¢les of hydrophobicity.
Another interesting observation is that the central 11-amino-
acid residue fragment, which is missing in non-amyloidogenic
human L-synuclein, does not represent the most hydrophobic
stretch in the NAC domain. Moreover, although between the
members of synuclein family the e⁄ciency of ¢brillation de-
creases in the following order: mouse K-synucleinsA53T -
s human K-synucleinsA30Pv human Q-synucleinEhuman
L-synuclein, the mean hydrophobicities of their NAC domains
calculated according to [39] form another trend: human
K-synuclein =A53T=A30P (0.5673)smouse K-synuclein
(0.5587)s human L-synuclein (0.5538)s human Q-synuclein
(0.5209). Finally, although human and mouse K-synucleins
show dramatic di¡erence in the ¢brillation rates [40], their
NAC domains di¡er only at a single position (Ser87 in human
vs. Asn87 in mouse). These observations call into question the
essential role of the central hydrophobic region of K-synuclein
and indicate the importance of additional interactions in
K-synuclein ¢brillation.
3.2. C-terminal domain
Fig. 3B shows that the hydrophobicity distributions within
the C-terminal domains of di¡erent members of synuclein
family vary dramatically. However, these domains possess
comparable mean hydrophobicities (calculated according to
[39]) : human Q-synuclein (0.3457)smouse K-synuclein
(0.3449)s human L-synuclein (0.3403)s human K-synuclein
=A53T=A30P (0.3348). Interestingly, the C-terminal do-
mains also di¡er signi¢cantly in their charge (net charges
are 34, 311, 312 and 316 for human Q-, mouse K-, human
K- and human L-synucleins, respectively). In fact, the C-ter-
minal domain of Q-synuclein, a protein which was shown to
form soluble oligomers most readily among the members of
synuclein family [33], has the smallest net charge (34), where-
as the carboxy-terminal part of non-amyloidogenic L-synu-
clein has the largest net charge (316). This suggests that the
charge and hydrophobicity distribution of the C-terminal do-
mains may play a role in the regulation of synuclein aggrega-
tion. In accord with this hypothesis it has been shown that
C-terminally truncated human K-synucleins (1^130, 1^120 and
1^110) assembled into ¢brils much more readily than the full-
length protein [13]. Finally, a hybrid protein, comprising the
¢rst 97 amino acids of human K-synuclein and the last 48 ami-
no acid residues of human L-synuclein, has been designed [33].
Although this hybrid protein contained a C-terminal domain
of slightly increased net charge (316 vs. 312), it was shown to
¢brillate as e⁄ciently as WT protein and formed ¢laments of
similar diameter and appearance [33].
3.3. N-terminal domain
The N-terminal domain has been revealed as another part
of the molecule that plays an important role in the modula-
tion of K-synuclein aggregation and ¢brillation, based on
comparison of the ¢brillation and aggregation rates of WT,
Fig. 3. Hydrophobicity distribution within NAC (A) and C-terminal
(B) fragments of optimally aligned sequences of K-, L- and Q-synu-
cleins from human and mouse K-synuclein.
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A30P and A53T human K-synucleins. It has been shown that
both familial PD mutations increase the rate of K-synuclein
oligomerization, whereas the rate of mature ¢bril formation
was increased by one (A53T) and decreased by the other
(A30P) [40^44]. High-resolution NMR analysis of these three
proteins established that the A30P mutation abolished a sig-
ni¢cant helical propensity found in an N-terminal stretch of
the WT protein [45]. From analysis of the CK chemical shifts
of this region it has been suggested that it preferentially
adopted a helical conformation (V10% of the time) in the
WT and A53T protein, but not in the A30P mutant [45]. As
for A53T, the structural alterations resulting from this muta-
tion were shown to be quite minor compared with those in-
duced by A30P, leading to the creation of a short contiguous
region with a local preference for extended backbone confor-
mation [45]. These observations are in a good agreement with
the results of the WT, A30P and A53T amino acid sequence
analyses in terms of hydrophobicity and propensity to form
K-helical or L-sheet structure [43]. The hydrophobicity of both
mutants is slightly reduced in the vicinity of substitutions [43].
This is an interesting observation, as it has been established
that both mutations accelerate aggregation and ¢brillation of
K-synuclein in vitro [40^44]. On the other hand, the propen-
sity to form K-helical structure is somewhat diminished in the
N-terminal regions of both the mutants. However, it has been
shown that A30P and A53T K-synucleins might be more
prone to form L-structure than WT K-synuclein [43,44]. It is
known that aggregated species of many proteins are enriched
in L-structure. Moreover, it has been established that trans-
formation of K-helical (or disordered) structure to L-sheets
(including intermolecular ones) is a hallmark of aggregation
and ¢brillation processes [46^55]. Taking into account these
observations it has been assumed that the increased propen-
sity for L-structure of A30P and A53T may not be enough to
alter the structure of the monomeric proteins, but may a¡ect
their aggregation behavior through speci¢c stabilization of an
intermolecular L-structure.
3.4. ‘Inhibitory’ substitutions
It has been shown that L- and Q-synucleins may inhibit the
¢brillation of K-synuclein [31,32]. Similarly, inhibition of ¢bril
formation has been reported for a mixture of human and
mouse K-synucleins [40]. Comparison of the sequences of
mouse K- and human K-, L- and Q-synucleins leads to an
interesting hypothesis concerning the existence of a unique
‘inhibitory’ substitution. There is only a single common resi-
due, Asn87 (located in the C-terminal part of NAC domains,
see Fig. 2) in the NAC domain in mouse K-, human L- and Q-
synucleins that is di¡erent from human K-synuclein, which has
serine at this position. Thus, we propose that the soluble
heterooligomers of human K- with mouse K-, or human L-,
or human Q-synucleins, which lead to the e¡ective suppression
of human K-synuclein ¢brillation, may be stabilized via spe-
ci¢c contacts involving Ser87-Asn87.
4. Concluding remarks
The following conclusions can be made about the sequence
determinants of K-synuclein aggregation and ¢brillation:
1. The NAC region is absolutely necessary for the aggregation
and ¢brillation of synucleins.
The C-terminal part of NAC (79^95 fragment) is not am-
yloidogenic, whereas the amino-terminal half of NAC, as
well as stretches of nine and more amino acid residues
derived from this part, is able to ¢brillate and to seed
¢brillation of full-length K-synuclein.
GXXX motifs of the NAC domain are not involved in
regulation of synuclein ¢brillation.
The C-terminal and N-terminal domains of K-synuclein are
important for the modulation of its aggregation and/or
¢brillation.
The amino acid residue at the position 87 may play an
important role in the inhibition of human K-synuclein ¢-
brillation by mouse K- or human L- or Q-synucleins.
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